Drug intelligence / Profile preview

curcumin + dexamethasone

Development stage: Preclinical
Modality: Small Molecules
Administration: Intranasal, Oral

Overview

A combination of curcumin, a natural phytochemical derived from turmeric with pleiotropic properties, and dexamethasone, a synthetic corticosteroid. This combination has demonstrated synergistic anti-inflammatory effects and has been studied for conditions including asthma exacerbations and multiple myeloma. The combination may provide therapeutic benefits while potentially reducing steroid-related side effects.

Targets

IL1B (Interleukin-1 beta)MMP9 (Matrix metalloproteinase-9)IL-5 (Interleukin 5)TLR4 (Toll-like receptor 4)CASP1 (Caspase-1)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on curcumin + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on curcumin + dexamethasone.

Explore the full profile